Ciencia básica y patogénesis

Área de la Ciencia:

• Neuroscience
• Genetics
• Molecular Biology

Sus antecedentes:

• Genomic and transcriptomic analyses reveal molecular pathway dysregulation in Alzheimer's disease (AD).
• The Hippo pathway effector YAP1 is dysregulated in AD and aggregates with amyloid.
• Suppression of Hippo kinase activity shows promise in AD animal models.

Objetivo del estudio:

• To explore the interaction between the Hippo pathway and Tau in Alzheimer's disease pathogenesis.
• To investigate how Hippo pathway dysregulation contributes to AD.
• To provide mechanistic insights into targeting the Hippo pathway therapeutically.

Principales métodos:

• Analysis of brain transcriptomes from AD patients and mouse models.
• Whole-exome sequencing to identify mutations in Hippo pathway genes.
• In vivo and in vitro assays (behavioral, biochemical, histopathological) to validate Hippo pathway-Tau interactions.

Principales resultados:

• Genomic analyses show increased mutations in Hippo pathway genes in AD patients.
• Transcriptomic data indicate Hippo pathway activation in AD.
• Hippo pathway modulation suppressed Tau-mediated neuronal dysfunction and reduced Tau levels in fly and human cell models.
• Tau and YAP1 were found to co-immunoprecipitate.

Conclusiones:

• Aberrant Hippo pathway activation and increased mutations are observed in Alzheimer's disease.
• Modulating Hippo pathway components effectively reduces Tau toxicity and lowers Tau protein levels.
• The Hippo pathway represents a potential diagnostic and therapeutic target for AD.